A window of opportunity trial (NCT04247282) is currently investigating the role of neoadjuvant TriAd vaccine along with anti-PD-L1/TGF-beta Trap (M7824) and anti-IL15 in patients with locally advanced, resectable stage II-IV HPV negative HNSCC. The gene discussed is IL15; the disease is head and neck squamous cell carcinoma.